Companies /Healthcare
Doximity Inc - Class A
NYSE: DOCS Health Information Services
$30.53
▼ $0.06 (−0.18%) today
Markets closed · 6:36pm ET

Doximity (DOCS) Q1 2027 Earnings

Reported Aug 6, 2026, 4:04pm ET · SEC source
$0.29
Miss −4.20%
EPS · est. $0.30 Adjusted
$156.6M
Beat +3.22%
Revenue · est. $151.7M
−10.3%
Trailing market
DOCS vs S&P since report
2 quarters
Consecutive EPS misses

How Did DOCS Stock React to Q1 2027 Earnings?

% change · around the report
0+50%+100%Aug 6Aug 7report 4:04pm ETearnings+0.6%+35.4%
0+50%+100%Aug 6Aug 7earnings+0.6%+35.4%
DOCS +35.4%S&P 500 +0.6%
0+60%+120%+180%Aug 6Aug 7report 4:04pm ETearnings+1.1%+35.4%
0+60%+120%+180%Aug 6Aug 7earnings+1.1%+35.4%
DOCS +35.4%NASDAQ +1.1%
−40%−20%0+20%Aug 5Aug 14report 4:04pm ETearnings+1.0%−28.9%
−40%−20%0+20%Aug 5Aug 14earnings+1.0%−28.9%
DOCS −28.9%S&P 500 +1.0%
−40%−20%0+20%Aug 5Aug 14report 4:04pm ETearnings+2.3%−28.9%
−40%−20%0+20%Aug 5Aug 14earnings+2.3%−28.9%
DOCS −28.9%NASDAQ +2.3%
+32.62%
Day of report
−6.46%
Next session
−9.49%
One week
−11.72%
30 days

S&P 500 over the same 30 days: −1.40%.

Did DOCS Beat Earnings? Q1 2027 Results

No. Doximity reported Q1 2027 earnings of $0.29 a share on Aug 6, 2026, missing the $0.30 consensus estimate by 4.2%. Revenue was $156.6M against a $151.7M estimate.

Doximity delivered a mixed fiscal first quarter for 2027, topping revenue expectations while falling short on profitability, a combination that sent shares lower amid broader concerns about demand trends. The medical networking platform posted revenue of $156.62 million, up 7.3% year-over-year and ahead of the $151.73 million consensus estimate, but adjusted non-GAAP diluted EPS of $0.29 missed the $0.30 analyst estimate by 4.20%. The earnings shortfall traced largely to surging costs, with stock-based compensation jumping roughly 68% to $36.75 million and research and development spending climbing to $38.48 million from $26.80 million a year ago, compressing GAAP net income margin from 36.5% to 15.5%. Adjusted EBITDA margin also contracted to 47.7% from 54.7%. Investors parsed the results with some caution, as softer billings raised questions about pharma marketing demand. Still, management pointed to strong AI product engagement and issued Q2 revenue guidance of $170 million to $171 million, while raising full-year revenue guidance to a range of $671 million to $681 million, signaling confidence in an acceleration ahead.

Key Takeaways
  • 7% year-over-year revenue growth driven by accelerated subscription revenue
  • Workflow active prescriber growth of more than 30% year-over-year
  • Record engagement on the platform
  • AI Search query growth of over 25% quarter-over-quarter

“We're proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement.”

Doximity CEO, on the earnings call

What Is Doximity's Outlook?

For fiscal Q2 2027 (ending September 30, 2026), Doximity guides revenue of $170 million to $171 million and adjusted EBITDA of $80.5 million to $81.5 million. For the full fiscal year ending March 31, 2027, the company updated guidance to revenue of $671 million to $681 million and adjusted EBITDA of $309 million to $329 million.

DOCS YoY Financials

Q1 2027 vs Q1 2026 · SEC filings Q1 2026 Q1 2027
$0$50.0M$100.0M$150.0M$145.9M$156.6MRevenue$130.1M$132.9MGross Profit$54.5M$33.6MOperating Income$53.3M$24.3MNet Income
$0$50.0M$100.0M$150.0MRevenueGross ProfitOperating IncomeNet Income
DOCS income statement, Q1 2027 versus Q1 2026
Metric Q1 2027 Q1 2026 Year over year
Revenue $156.6M $145.9M +7.3%
Gross Profit $132.9M $130.1M +2.2%
Operating Income $33.6M $54.5M −38.3%
Net Income $24.3M $53.3M −54.4%

DOCS Revenue by Segment

Subscription Revenue

When Does Doximity Report Next?

Expected report date

Figures from SEC filings and company reports. Not investment advice.